Ariel Berger

Ariel Berger, MPH, is an Executive Director, Integrated Solutions, U.S. Database Analytics with PPD™ Evidera™ Real-World Data & Scientific Solutions (RWD&SS) at Thermo Fisher Scientific and is located in Massachusetts. In Mr. Berger’s current position, he helps lead the Database Analytics Business Unit, contributing to internal processes, staff development and training, and development of new customer offerings; he also designs and leads/advises on various RWE and health economics studies, often involving complex methodologies and hybrid designs and disciplines, and strategic initiatives, such as data landscaping and evidence generation planning, and the company’s AI- and technology-enabled offerings in this space. Prior to joining Evidera, he was a senior consultant with Policy Analysis Inc. for approximately 13 years, during which time he led numerous outcomes research studies, including retrospective database analyses; developed health economic models (both budgetary impact and cost effectiveness models); performed literature reviews; and prepared product dossiers.

Mr. Berger has experience across a wide range of therapeutic areas, including but not limited to pulmonary arterial hypertension, infectious diseases, oncology, cardiovascular disease, osteoarthritis, neuropathic pain, fibromyalgia, migraine headache, mental health disorders, end-stage renal disease, and ostomy/incontinence care. His related work has been published in peer-reviewed journals including Surgical Infections, Pain Practice, Journal of Health and Productivity, American Journal of Managed Care, Infection Control and Hospital Epidemiology, Annals of Pharmacotherapy, and BMC Pulmonary Medicine. His work has been presented at conferences such as the American Thoracic Society (ATS), the European Society of Clinical Microbiology and Infectious Diseases (ECMID), the American Society of Nephrology (ASN), the Infectious Diseases Society of America (IDSA), and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Mr. Berger has an MPH with a concentration in epidemiology and biostatistics from the Boston University School of Public Health and a BA from Syracuse University